Safety and Efficacy of the BNT162b2 mRNA Covid-19 VaccineFernando P. Polack, William C. Gruber, Stephen J. Thomas et al.|New England Journal of Medicine|2020Cited by 15.7k
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine CandidatesEdward E. Walsh, William C. Gruber, Robert W. Frenck et al.|New England Journal of Medicine|2020Cited by 2.7k
Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adultsMark J. Mulligan, Kathrin U. Jansen, Kirsten E. Lyke et al.|Nature|2020Cited by 1.6k
Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in AdolescentsRobert W. Frenck, William C. Gruber, Nicola P. Klein et al.|New England Journal of Medicine|2021Cited by 937
SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3Ann R. Falsey, William C. Gruber, Robert W. Frenck et al.|New England Journal of Medicine|2021Cited by 420